KangLaiTe USA (KLT USA) is a privately held biotechnology company developing a treatment for solid tumors and for cancer-associated anorexia-cachexia syndrome. Our Management Team consists of industry leaders with extensive experience in the pharmaceutical industry. In 1995, the company’s lead product under development, Kanglaite Injection (KLTi), was approved by the Chinese Ministry of Health for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and hepatocellular cancer, and it was approved in Russia for treatment of patients with advanced NSCLC in 2003. Today the company holds three open Investigational New Drug applications (INDs) with the U.S. Food & Drug Administration (FDA) for indications related to the treatment of cancer, and KLTi has just completed a phase II clinical trial in the U.S. The company’s mission is to discover and develop natural therapies to improve the lives of people living with various cancers, including pancreatic cancer and prostate cancer.